Objective Metadoxine is approved in Europe for alcohol intoxication and is also indicated for alcoholic liver disease (ALD). This study aims to investigate the use of metadoxine as a potential pharmacotherapy for alcohol dependence (AD). Methods This is a retrospective study of 94 outpatients with AD, who received metadoxine for alcohol intoxication and were assessed for alcohol consumption, craving [Visual Analog Scale (VAS)] and liver-related and alcohol-related biomarkers [aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl-transpeptidase, mean corpuscular volume]. Results Range of metadoxine dose was 500-2000mg/day, with a mean dose of 1277(s.d.290)mg/day, and for a period of 2-42days, with a mean period of 8.9(s.d.7.0)days. Follow-up data were available for 52 patients (55.3%); 35(67.3%) patients were completely abstinent. There was a significant decrease in drinks per week, even after substituting baseline drinking as follow-up data for dropouts (p<0.001) and examining drinking pre-treatment and post-treatment for those who did not achieve abstinence (p<0.001). There was a significant decrease in the VAS (p<0.001) and a significant improvement in the AST/ALT ratio (p=0.03). Discussion Despite important limitations, this study represents a further preliminary observation suggesting metadoxine as a novel alcohol pharmacotherapy, including in alcohol-dependent patients with ALD.
Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease / L. Leggio, G.A. Kenna, A. Ferrulli, W.H. Zywiak, F. Caputo, R.M. Swift, G. Addolorato. - In: HUMAN PSYCHOPHARMACOLOGY. - ISSN 0885-6222. - 26:8(2011), pp. 554-559.
Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease
A. Ferrulli;F. Caputo;
2011
Abstract
Objective Metadoxine is approved in Europe for alcohol intoxication and is also indicated for alcoholic liver disease (ALD). This study aims to investigate the use of metadoxine as a potential pharmacotherapy for alcohol dependence (AD). Methods This is a retrospective study of 94 outpatients with AD, who received metadoxine for alcohol intoxication and were assessed for alcohol consumption, craving [Visual Analog Scale (VAS)] and liver-related and alcohol-related biomarkers [aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl-transpeptidase, mean corpuscular volume]. Results Range of metadoxine dose was 500-2000mg/day, with a mean dose of 1277(s.d.290)mg/day, and for a period of 2-42days, with a mean period of 8.9(s.d.7.0)days. Follow-up data were available for 52 patients (55.3%); 35(67.3%) patients were completely abstinent. There was a significant decrease in drinks per week, even after substituting baseline drinking as follow-up data for dropouts (p<0.001) and examining drinking pre-treatment and post-treatment for those who did not achieve abstinence (p<0.001). There was a significant decrease in the VAS (p<0.001) and a significant improvement in the AST/ALT ratio (p=0.03). Discussion Despite important limitations, this study represents a further preliminary observation suggesting metadoxine as a novel alcohol pharmacotherapy, including in alcohol-dependent patients with ALD.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.